Preprocedural anticoagulation does not reduce angioplasty heparin requirements

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Percutaneous transluminal coronary angioplasty (PTCA) requires careful anticoagulation management.
• The impact of continuous preprocedural heparinization on intraprocedural anticoagulation needs in PTCA is not fully understood.

Purpose of the Study:

• To investigate whether continuous preprocedural heparin administration influences the total amount of heparin required during PTCA.
• To compare heparin requirements between patients pretreated with heparin and a control group.

Main Methods:

• A comparative study involving patients undergoing PTCA.
• Monitoring of activated clotting time (ACT) using a Hemochron device to ensure optimal anticoagulation (ACT > or = 300 seconds).
• Comparison of preprocedural ACT and partial thromboplastin time (PTT) values, and total heparin dosage between pretreated and control groups.

Main Results:

• Patients receiving continuous preprocedural heparin had significantly higher baseline ACT and PTT values.
• While control patients required slightly more heparin initially, the total heparin dosage to maintain ACT > 300 seconds throughout the procedure was similar between groups.
• No significant reduction in total heparin requirements was observed in the pretreated group.

Conclusions:

• Continuous preprocedural heparinization does not significantly reduce the total heparin required during PTCA.
• Patients undergoing PTCA should receive the same initial intravenous heparin regimen, irrespective of preprocedural heparin treatment.